Literature DB >> 15212010

4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization -- organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 23-25, June 2003.

J Richard Pink1, Marie-Paule Kieny.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15212010     DOI： 10.1016/j.vaccine.2004.01.021

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  16 in total

1.  The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

2.  Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens.

Authors:  Jigna D Patel; Ronan O'Carra; Julia Jones; Jerold G Woodward; Russell J Mumper
Journal:  Pharm Res       Date:  2006-12-19       Impact factor: 4.200

3.  Design and synthesis of potent Quillaja saponin vaccine adjuvants.

Authors:  Michelle M Adams; Payal Damani; Nicholas R Perl; Annie Won; Feng Hong; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  J Am Chem Soc       Date:  2010-02-17       Impact factor: 15.419

4.  Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.

Authors:  S A Kaba; A Price; Z Zhou; V Sundaram; P Schnake; I F Goldman; A A Lal; V Udhayakumar; C W Todd
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

5.  Versatile strategy for the divergent synthesis of linear oligosaccharide domain variants of Quillaja saponin vaccine adjuvants.

Authors:  Alberto Fernández-Tejada; Derek S Tan; David Y Gin
Journal:  Chem Commun (Camb)       Date:  2015-09-21       Impact factor: 6.222

6.  Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.

Authors:  Alberto Fernández-Tejada; Eric K Chea; Constantine George; Jeffrey R Gardner; Philip O Livingston; Govind Ragupathi; Derek S Tan; David Y Gin
Journal:  Bioorg Med Chem       Date:  2014-09-17       Impact factor: 3.641

7.  Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.

Authors:  Patrick Georges Cech; Thomas Aebi; Mwanajaa Shomari Abdallah; Maxmillian Mpina; Ester Barnabas Machunda; Nicole Westerfeld; Sabine Alexandra Stoffel; Rinaldo Zurbriggen; Gerd Pluschke; Marcel Tanner; Claudia Daubenberger; Blaise Genton; Salim Abdulla
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

8.  Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.

Authors:  Feng Qian; Yimin Wu; Olga Muratova; Hong Zhou; Gelu Dobrescu; Peter Duggan; Lambert Lynn; Guanhong Song; Yanling Zhang; Karine Reiter; Nicholas MacDonald; David L Narum; Carole A Long; Louis H Miller; Allan Saul; Gregory E D Mullen
Journal:  Vaccine       Date:  2007-03-13       Impact factor: 4.169

9.  A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.

Authors:  Blaise Genton; Gerd Pluschke; Lukas Degen; Andreas R Kammer; Nicole Westerfeld; Shinji L Okitsu; Sandro Schroller; Penelope Vounatsou; Markus M Mueller; Marcel Tanner; Rinaldo Zurbriggen
Journal:  PLoS One       Date:  2007-10-10       Impact factor: 3.240

10.  Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.

Authors:  David R Cavanagh; Clemens H M Kocken; John H White; Graeme J M Cowan; Kay Samuel; Martin A Dubbeld; Annemarie Voorberg-van der Wel; Alan W Thomas; Jana S McBride; David E Arnot
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.